{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:14:01Z","timestamp":1782422041825,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.medj.2023.10.005","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:14:24Z","timestamp":1699614864000},"page":"752-754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?"],"prefix":"10.1016","volume":"4","author":[{"given":"Mohamed A.","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw Z.","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2023.10.005_bib1","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.3390\/curroncol30090574","article-title":"An Overview of Endometrial Cancer with Novel Therapeutic Strategies","volume":"30","author":"Kuhn","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.medj.2023.10.005_bib2","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2023.10.005_bib3","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.10.005_bib4","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.10.005_bib5","first-page":"JCO2202906","article-title":"Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer","author":"Vergote","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2023.10.005_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1-from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2023.10.005_bib7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s10637-021-01119-0","article-title":"Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study","volume":"39","author":"Thein","year":"2021","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.medj.2023.10.005_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2020.10.019","article-title":"A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers","volume":"160","author":"Rubinstein","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.medj.2023.10.005_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","article-title":"Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.medj.2023.10.005_bib10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/path.5034","article-title":"The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses","volume":"244","author":"McAlpine","year":"2018","journal-title":"J.\u00a0Pathol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023003355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023003355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:58:11Z","timestamp":1763002691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634023003355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666634023003355"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2023.10.005","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2023.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}